Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus docetaxel as second-line therapy in EGFR wild-type advanced non-squamous NSCLC
ChiCTR-OPN-16008694Phase 4Not yet recruiting
- Sponsor
- Huizhou Central People's Hospital
- Start
- Aug 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Huizhou Central People's Hospital. Primary endpoint: progression-free survival. Planned start Aug 2017; status: not yet recruiting.
02
Drugs
Rivoceranibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPN-16008694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPN-16008694.